Literature DB >> 2115039

Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency.

S Chamberland1, F Malouin, H R Rabin, T Schollaardt, T R Parr, L E Bryan.   

Abstract

The mechanism of persistence was characterized in Pseudomonas aeruginosa isolates obtained ten days before (4405), on the tenth day of (4419), and four days after (4478) ciprofloxacin therapy in a cystic fibrosis patient. Isolate 4419 showed a 16-fold increase in resistance to ciprofloxacin, norfloxacin and nalidixic acid. The outer membrane of 4419 had no detectable protein F. A modified lipopolysaccharide profile, a longer lag phase before growth and a slower generation time were also noted for isolate 4419. Cell surface hydrophobicity was increased by 20% in 4419 whereas uptake of [14C]ciprofloxacin was equivalent in all three isolates. Ciprofloxacin doses causing 50% inhibition of DNA synthesis were proportional to MICs for each isolate indicating that the DNA gyrase of 4419 was resistant to quinolones. A quinolone-susceptible revertant of 4419 remained deficient in protein F. Protein F-deficiency was not associated with resistance to quinolones, nor to other antibiotics, supporting the view that it plays little role in outer membrane permeability to antibiotics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115039     DOI: 10.1093/jac/25.6.995

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.

Authors:  L J Piddock; M C Hall; F Bellido; M Bains; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

Authors:  J M Diver; T Schollaardt; H R Rabin; C Thorson; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

3.  Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  M I Ferguson; E M Scott; P S Collier
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin.

Authors:  J Vila; J Ruiz; F Sanchez; F Navarro; B Mirelis; M T de Anta; G Prats
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa.

Authors:  M Michéa-Hamzehpour; Y X Furet; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.

Authors:  N Lehn; J Stower-Hoffmann; T Kott; C Strassner; H Wagner; M Kronke; W Schneider-Brachert
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

7.  Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Luke Guo; Peter Working; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 8.  Fluoroquinolones in the treatment of cystic fibrosis.

Authors:  N Høiby; S S Pedersen; T Jensen; N H Valerius; C Koch
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients.

Authors:  M J Struelens; V Schwam; A Deplano; D Baran
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

10.  Fluoroquinolone supersusceptibility mediated by outer membrane protein OprH overexpression in Pseudomonas aeruginosa: evidence for involvement of a nonporin pathway.

Authors:  M Young; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.